APLS [NASD]
Apellis Pharmaceuticals, Inc.
Index- P/E- EPS (ttm)-8.02 Insider Own2.70% Shs Outstand98.07M Perf Week14.37%
Market Cap4.70B Forward P/E- EPS next Y-4.53 Insider Trans-2.43% Shs Float88.42M Perf Month-7.92%
Income-701.60M PEG- EPS next Q-1.28 Inst Own86.30% Short Float9.97% Perf Quarter4.10%
Sales80.90M P/S58.06 EPS this Y-92.70% Inst Trans12.15% Short Ratio7.14 Perf Half Y1.12%
Book/sh4.71 P/B9.43 EPS next Y18.30% ROA-86.30% Target Price72.36 Perf Year-5.89%
Cash/sh9.13 P/C4.87 EPS next 5Y33.30% ROE-607.40% 52W Range27.50 - 73.00 Perf YTD-6.05%
Dividend- P/FCF- EPS past 5Y- ROI-86.10% 52W High-39.15% Beta1.59
Dividend %- Quick Ratio8.60 Sales past 5Y- Gross Margin92.00% 52W Low61.53% ATR3.28
Employees476 Current Ratio8.80 Sales Q/Q-75.90% Oper. Margin- RSI (14)50.80 Volatility7.94% 8.23%
OptionableYes Debt/Eq1.18 EPS Q/Q38.90% Profit Margin- Rel Volume0.50 Prev Close44.81
ShortableYes LT Debt/Eq1.17 EarningsMay 04 AMC Payout- Avg Volume1.23M Price44.42
Recom1.90 SMA204.40% SMA50-6.79% SMA2000.11% Volume617,682 Change-0.87%
Apr-14-22Downgrade ROTH Capital Neutral → Sell $40
Dec-08-21Initiated Wells Fargo Overweight $84
Nov-29-21Downgrade ROTH Capital Buy → Neutral $46 → $40
Sep-10-21Reiterated Oppenheimer Outperform $80 → $65
Sep-10-21Reiterated Needham Buy $85 → $70
Sep-10-21Reiterated Credit Suisse Neutral $50 → $38
Sep-10-21Reiterated BMO Capital Markets Outperform $89 → $69
Sep-10-21Downgrade Wedbush Outperform → Neutral $71 → $39
Aug-19-21Upgrade Wedbush Neutral → Outperform
Aug-19-21Initiated Jefferies Buy $74
May-21-21Initiated UBS Buy $82
Apr-16-21Initiated Goldman Buy $130
Nov-19-20Initiated Needham Buy $59
Sep-01-20Initiated Stifel Buy $40
Jul-20-20Initiated ROTH Capital Buy $50
Jun-17-20Initiated BTIG Research Neutral
Apr-01-20Initiated Raymond James Strong Buy $86
Mar-31-20Initiated BMO Capital Markets Outperform $54
Mar-11-20Upgrade Wedbush Underperform → Neutral $29
Jan-07-20Initiated SVB Leerink Mkt Perform $30
May-12-22 11:05AM  
May-06-22 04:23PM  
09:55AM  
May-05-22 04:05PM  
10:04AM  
May-04-22 06:15PM  
04:05PM  
May-03-22 07:00AM  
May-02-22 03:30PM  
Apr-26-22 07:00AM  
Apr-22-22 01:19PM  
Apr-21-22 07:00AM  
Apr-11-22 11:46AM  
Apr-04-22 02:53PM  
07:00AM  
Mar-30-22 11:30AM  
Mar-29-22 01:03PM  
Mar-28-22 04:01PM  
Mar-24-22 07:00AM  
Mar-23-22 04:03PM  
Mar-16-22 04:07PM  
11:41AM  
08:37AM  
07:00AM  
Mar-02-22 07:00AM  
Mar-01-22 09:34AM  
Feb-28-22 05:45PM  
04:05PM  
Feb-24-22 07:55AM  
Feb-23-22 11:11AM  
08:43AM  
Feb-22-22 07:00AM  
Feb-21-22 11:26AM  
Feb-17-22 03:03PM  
Feb-10-22 04:45AM  
Feb-07-22 11:36AM  
Feb-02-22 01:38PM  
Jan-24-22 01:38PM  
Jan-19-22 01:38PM  
Jan-06-22 04:05PM  
Jan-03-22 12:05PM  
07:00AM  
Dec-23-21 05:38AM  
Dec-16-21 09:38AM  
Dec-15-21 10:14AM  
07:00AM  
Dec-13-21 11:45AM  
Dec-10-21 08:10AM  
Dec-09-21 09:31AM  
Nov-29-21 07:00AM  
Nov-18-21 04:01PM  
Nov-16-21 07:00AM  
Nov-15-21 04:01PM  
Nov-12-21 07:00AM  
Nov-10-21 07:00AM  
Nov-09-21 10:45AM  
Nov-08-21 05:15PM  
04:01PM  
Nov-04-21 09:17AM  
Nov-03-21 07:00AM  
Nov-01-21 07:00AM  
Oct-25-21 03:01PM  
Oct-21-21 02:21AM  
Oct-18-21 10:20AM  
10:17AM  
Oct-15-21 07:17AM  
Oct-06-21 04:05PM  
Sep-30-21 11:49AM  
Sep-22-21 12:02PM  
Sep-20-21 07:00AM  
Sep-13-21 11:02AM  
Sep-10-21 04:11PM  
03:07PM  
12:49PM  
12:31PM  
11:39AM  
10:58AM  
10:52AM  
10:40AM  
10:21AM  
08:00AM  
06:35AM  
Sep-09-21 04:05PM  
Sep-08-21 11:30AM  
Sep-07-21 04:05PM  
Sep-03-21 04:05PM  
Aug-11-21 08:36AM  
Aug-10-21 03:36PM  
Aug-09-21 05:25PM  
04:01PM  
Aug-06-21 04:05PM  
Aug-02-21 01:51AM  
Jul-29-21 08:33AM  
07:00AM  
Jul-26-21 07:00AM  
Jul-07-21 10:06PM  
04:05PM  
Jul-06-21 07:42AM  
Jul-02-21 09:19AM  
Jun-30-21 04:15PM  
Apellis Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic compounds through the inhibition of the complement system for autoimmune and inflammatory diseases. The company's lead product candidate is pegcetacoplan that is in Phase III clinical trials for the treatment of geographic atrophy (GA) in age-related macular degeneration and paroxysmal nocturnal hemoglobinuria (PNH) diseases. It also develops EMPAVELI (systemic pegcetacoplan) for the treatment of cold agglutinin disease (CAD), and hematopoietic stem cell transplantation-associated thrombotic microangiopathy (HSCT-TMA) in hematology; C3 glomerulopathy (C3G), and immune complex membranoproliferative glomerulonephritis (IC-MPGN) in nephrology; and amyotrophic lateral sclerosis (ALS) in neurology. In addition, the company develops APL-2006, a bispecific C3 and VEGF inhibitor for treating complement-mediated disorders; APL-1030, a C3 inhibitor for the treatment of multiple neurodegenerative diseases; and the combination of EMPAVELI and a small interfering RNA, or siRNA for reducing the production of C3 proteins by the liver. It has a collaboration and license agreement with Swedish Orphan Biovitrum AB (publ) to co-develop pegcetacoplan; and a research collaboration with Beam Therapeutics Inc. focused on the use of Beam's base editing technology to discover new treatments for complement-driven diseases. Apellis Pharmaceuticals, Inc. was incorporated in 2009 and is based in Waltham, Massachusetts.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Machiels AlecDirectorMay 16Option Exercise2.671,2503,338265,024May 17 05:26 PM
Machiels AlecDirectorMay 16Sale39.181,25048,975263,774May 17 05:26 PM
Grossi FedericoCHIEF MEDICAL OFFICERMay 02Sale43.562,500108,900112,061May 03 07:56 PM
Deschatelets PascalChief Scientific OfficerApr 29Option Exercise2.674,00010,680895,775May 02 08:05 PM
Deschatelets PascalChief Scientific OfficerApr 29Sale44.434,000177,720891,775May 02 08:05 PM
Watson David O.General CounselApr 25Sale50.005,000250,000125,569Apr 27 04:39 PM
Dunlop A. SinclairDirectorApr 22Option Exercise14.0020,000280,00091,124Apr 25 09:35 PM
DeLong Mark JeffreySenior Vice PresidentApr 20Option Exercise15.527,000108,64035,481Apr 22 05:35 PM
DeLong Mark JeffreySenior Vice PresidentApr 20Sale52.537,000367,71028,481Apr 22 05:35 PM
Machiels AlecDirectorApr 14Option Exercise2.671,2503,338265,024Apr 18 07:42 PM
Machiels AlecDirectorApr 14Sale50.901,25063,625263,774Apr 18 07:42 PM
SCHEIBLER LUKASCHIEF INNOVATION OFFICERApr 05Option Exercise13.856098,43552,842Apr 06 04:10 PM
SCHEIBLER LUKASCHIEF INNOVATION OFFICERApr 05Sale60.0960936,59352,233Apr 06 04:10 PM
SCHEIBLER LUKASCHIEF INNOVATION OFFICERApr 04Option Exercise13.853,50448,53055,737Apr 05 04:08 PM
SCHEIBLER LUKASCHIEF INNOVATION OFFICERApr 04Sale56.963,504199,58952,233Apr 05 04:08 PM
SCHEIBLER LUKASCHIEF INNOVATION OFFICERApr 01Option Exercise13.8511,496159,22063,729Apr 04 05:03 PM
SCHEIBLER LUKASCHIEF INNOVATION OFFICERApr 01Sale55.0511,496632,85552,233Apr 04 05:03 PM
Machiels AlecDirectorMar 15Option Exercise2.671,2503,338260,794Mar 17 08:59 PM
Grossi FedericoCHIEF MEDICAL OFFICERMar 15Option Exercise4.317,00030,170116,811Mar 17 06:19 PM
Grossi FedericoCHIEF MEDICAL OFFICERMar 15Sale39.5737514,839116,436Mar 17 06:19 PM
Machiels AlecDirectorMar 15Sale39.571,25049,462259,544Mar 17 08:59 PM
Grossi FedericoCHIEF MEDICAL OFFICERMar 01Sale43.5337516,324109,811Mar 02 06:15 PM
Grossi FedericoCHIEF MEDICAL OFFICERFeb 23Option Exercise4.314,10017,671110,186Feb 24 04:33 PM
Machiels AlecDirectorFeb 15Option Exercise2.671,2503,338675,024Feb 16 04:29 PM
Machiels AlecDirectorFeb 15Sale45.431,25056,788673,774Feb 16 04:29 PM
Grossi FedericoCHIEF MEDICAL OFFICERFeb 15Sale45.4337517,036106,086Feb 16 04:29 PM
Grossi FedericoCHIEF MEDICAL OFFICERFeb 14Option Exercise4.313,60015,516106,461Feb 15 04:59 PM
SCHEIBLER LUKASCHIEF INNOVATION OFFICERFeb 14Option Exercise26.7372019,24652,233Feb 15 04:58 PM
SCHEIBLER LUKASCHIEF INNOVATION OFFICERFeb 11Sale46.801,66677,96951,513Feb 14 06:20 PM
SCHEIBLER LUKASCHIEF INNOVATION OFFICERFeb 08Option Exercise13.8510,000138,50063,857Feb 10 08:32 AM
SCHEIBLER LUKASCHIEF INNOVATION OFFICERFeb 08Sale45.0010,000450,00053,857Feb 10 08:32 AM
Grossi FedericoCHIEF MEDICAL OFFICERFeb 01Sale40.5837515,218103,566Feb 02 04:50 PM
SCHEIBLER LUKASCHIEF INNOVATION OFFICERJan 31Sale38.471,23347,43453,857Feb 01 05:58 PM
SCHEIBLER LUKASCHIEF INNOVATION OFFICERJan 21Option Exercise26.733,02180,75129,681Jan 24 05:26 PM
Grossi FedericoCHIEF MEDICAL OFFICERJan 14Option Exercise4.313,40014,65478,915Jan 19 08:03 PM
Machiels AlecDirectorJan 14Option Exercise2.671,2503,338675,024Jan 19 08:15 PM
Grossi FedericoCHIEF MEDICAL OFFICERJan 14Sale40.5637515,21078,540Jan 19 08:03 PM
Machiels AlecDirectorJan 14Sale40.561,25050,700673,774Jan 19 08:15 PM
Grossi FedericoCHIEF MEDICAL OFFICERJan 12Option Exercise3.925,16120,23075,515Jan 14 04:57 PM
Grossi FedericoCHIEF MEDICAL OFFICERJan 03Sale47.3137517,74170,354Jan 04 04:07 PM
Watson David O.General CounselDec 27Sale48.501,20058,200107,534Dec 28 05:38 PM
Watson David O.General CounselDec 22Option Exercise14.4020,112289,674114,131Dec 23 04:58 PM
Watson David O.General CounselDec 22Sale47.8110,571505,373104,019Dec 23 04:58 PM
Machiels AlecDirectorDec 15Option Exercise2.673,0008,010672,544Dec 17 05:09 PM
Grossi FedericoCHIEF MEDICAL OFFICERDec 15Sale42.8837516,08070,729Dec 17 05:10 PM
Machiels AlecDirectorDec 15Sale42.883,000128,640669,544Dec 17 05:09 PM
Grossi FedericoCHIEF MEDICAL OFFICERDec 08Option Exercise3.767,00026,32071,104Dec 09 04:57 PM
Grossi FedericoCHIEF MEDICAL OFFICERDec 01Sale42.4037515,90064,104Dec 03 04:00 PM
Morningside Venture Investment10% OwnerNov 18Buy40.00250,00010,000,00012,806,342Nov 18 04:16 PM
Machiels AlecDirectorNov 15Option Exercise2.673,0008,010672,544Nov 17 05:01 PM
Machiels AlecDirectorNov 15Sale43.503,000130,500669,544Nov 17 05:01 PM
Grossi FedericoCHIEF MEDICAL OFFICERNov 15Sale43.5062527,18864,479Nov 17 05:02 PM
Machiels AlecDirectorNov 04Option Exercise2.673,0008,010672,544Nov 17 05:01 PM
Machiels AlecDirectorNov 04Sale35.003,000105,000669,544Nov 17 05:01 PM
Grossi FedericoCHIEF MEDICAL OFFICERNov 01Sale30.7062519,18864,805Nov 02 04:01 PM
Grossi FedericoCHIEF MEDICAL OFFICEROct 14Sale34.5775025,92865,430Oct 15 04:02 PM
Grossi FedericoCHIEF MEDICAL OFFICEROct 01Sale33.2675024,94566,180Oct 05 04:16 PM
Grossi FedericoCHIEF MEDICAL OFFICERSep 28Option Exercise3.764,00015,04066,930Sep 29 09:48 PM
Dunlop A. SinclairDirectorSep 10Option Exercise14.006,89496,51666,894Sep 13 04:10 PM
Watson David O.General CounselSep 10Option Exercise4.319544,11299,193Sep 13 04:08 PM
Machiels AlecDirectorAug 16Option Exercise2.672,5006,675672,044Aug 17 04:42 PM
Machiels AlecDirectorAug 16Sale56.952,500142,375669,544Aug 17 04:42 PM
Perry Nicole DVice President - AccountingAug 02Option Exercise3.761,0003,7605,847Aug 03 04:23 PM
Grossi FedericoCHIEF MEDICAL OFFICERAug 02Sale63.9925015,99862,930Aug 03 04:26 PM
Perry Nicole DVice President - AccountingAug 02Sale63.991,00063,9904,847Aug 03 04:23 PM
DeLong Mark JeffreySenior Vice PresidentJul 21Option Exercise15.521,00015,52010,490Jul 22 04:24 PM
Francois CedricChief Executive OfficerJul 21Option Exercise4.3114,41062,1071,234,243Jul 22 04:04 PM
DeLong Mark JeffreySenior Vice PresidentJul 21Sale65.001,00065,0009,490Jul 22 04:24 PM
DeLong Mark JeffreySenior Vice PresidentJul 15Option Exercise15.521,00015,52010,490Jul 16 06:40 PM
Machiels AlecDirectorJul 15Option Exercise2.672,5006,675672,044Jul 16 06:38 PM
DeLong Mark JeffreySenior Vice PresidentJul 15Sale62.301,00062,3009,490Jul 16 06:40 PM
Machiels AlecDirectorJul 15Sale62.302,500155,750669,544Jul 16 06:38 PM
Grossi FedericoCHIEF MEDICAL OFFICERJul 14Sale64.6850032,34063,180Jul 15 04:56 PM
Grossi FedericoCHIEF MEDICAL OFFICERJul 08Sale65.6825016,42063,680Jul 09 03:59 PM
Grossi FedericoCHIEF MEDICAL OFFICERJun 28Option Exercise3.769,00033,84063,930Jun 29 04:58 PM
Deschatelets PascalChief Scientific OfficerJun 24Option Exercise2.676,25016,688875,837Jun 25 09:48 PM
Deschatelets PascalChief Scientific OfficerJun 24Sale65.616,250410,062869,587Jun 25 09:48 PM
Watson David O.General CounselJun 21Option Exercise4.314892,10898,239Jun 22 04:02 PM
Machiels AlecDirectorJun 15Option Exercise2.672,5006,675672,044Jun 16 04:33 PM
DeLong Mark JeffreySenior Vice PresidentJun 15Option Exercise15.524,00062,08013,490Jun 16 04:32 PM
Machiels AlecDirectorJun 15Sale64.832,500162,075669,544Jun 16 04:33 PM
DeLong Mark JeffreySenior Vice PresidentJun 15Sale64.964,000259,8309,490Jun 16 04:32 PM
Grossi FedericoCHIEF MEDICAL OFFICERJun 14Sale61.8450030,92054,930Jun 15 04:03 PM
Perry Nicole DVice President - AccountingJun 11Option Exercise3.201,0003,2005,847Jun 15 04:04 PM
Perry Nicole DVice President - AccountingJun 11Sale61.551,00061,5554,847Jun 15 04:04 PM
SCHEIBLER LUKASCHIEF INNOVATION OFFICERJun 10Sale60.003,417205,02026,651Jun 11 04:07 PM
Sullivan Timothy EugeneChief Financial OfficerJun 08Option Exercise10.0339,880399,99674,141Jun 09 04:06 PM
Perry Nicole DVice President - AccountingJun 01Option Exercise3.761,0003,7605,847Jun 02 04:15 PM
Perry Nicole DVice President - AccountingJun 01Sale56.401,00056,4004,847Jun 02 04:15 PM
Watson David O.General CounselMay 28Option Exercise4.314892,10897,750Jun 01 04:53 PM
Deschatelets PascalChief Scientific OfficerMay 24Option Exercise2.676,25016,688875,837May 25 04:01 PM
Deschatelets PascalChief Scientific OfficerMay 24Sale47.406,250296,250869,587May 25 04:01 PM